"Artificial Intelligence-Enabled Assessment of Right Ventricular to Pulmonary Artery Coupling in Patients Undergoing Transcatheter Tricuspid Valve Intervention".

Tricuspid regurgitation artificial intelligence right ventricular to pulmonary artery coupling transcatheter tricuspid valve intervention

Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
23 Nov 2023
Historique:
received: 26 08 2023
revised: 09 10 2023
accepted: 12 10 2023
medline: 24 11 2023
pubmed: 24 11 2023
entrez: 23 11 2023
Statut: aheadofprint

Résumé

Right ventricular to pulmonary artery (RV-PA) coupling has been established as a prognostic marker in patients with severe tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve interventions (TTVI). RV-PA coupling assesses right ventricular systolic function related to pulmonary artery pressure levels, which are ideally measured by right heart catheterization. This study aims to improve the RV-PA coupling concept by relating tricuspid annular plane systolic excursion (TAPSE) to mean pulmonary artery pressure (mPAP) levels. Moreover, instead of right heart catheterization, this study sought to employ an extreme gradient boosting (XGB) algorithm to predict mPAP levels based on standard echocardiographic parameters. This multicenter study included 737 patients undergoing TTVI for severe TR; among them, 55 patients from one institution served for external validation. Complete echocardiography and right heart catheterization data were available from all patients. The XGB algorithm trained on 10 echocardiographic parameters could reliably predict mPAP levels as evaluated on right heart catheterization data from external validation (Pearson correlation coefficient R: 0.68; p-value: 1.3x10-8). Moreover, predicted mPAP (mPAPpredicted) levels were superior to echocardiographic systolic pulmonary artery pressure (sPAPechocardiography) levels in predicting 2-year mortality after TTVI (area under the curve [AUC]: 0.607 vs. 0.520; p-value: 1.9x10-6). Furthermore, TAPSE/mPAPpredicted was superior to TAPSE/sPAPechocardiography in predicting 2-year mortality after TTVI (AUC: 0.633 vs. 0.586; p-value: 0.008). Finally, patients with preserved RV-PA coupling (defined as TAPSE/mPAPpredicted > 0.617 mm/mmHg) showed significantly higher 2-year survival rates after TTVI than patients with reduced RV-PA coupling (81.5% vs. 58.8%, p-value: < 0.001). Moreover, independent association between TAPSE/mPAPpredicted levels and 2-year mortality after TTVI was confirmed by multivariate regression analysis (p-value: 6.3x10-4). Artificial intelligence-enabled RV-PA coupling assessment can refine risk stratification prior to TTVI without necessitating invasive right heart catheterization. A comparison with conservatively treated patients is mandatory to quantify the benefit of TTVI in accordance with RV-PA coupling.

Sections du résumé

BACKGROUND BACKGROUND
Right ventricular to pulmonary artery (RV-PA) coupling has been established as a prognostic marker in patients with severe tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve interventions (TTVI). RV-PA coupling assesses right ventricular systolic function related to pulmonary artery pressure levels, which are ideally measured by right heart catheterization. This study aims to improve the RV-PA coupling concept by relating tricuspid annular plane systolic excursion (TAPSE) to mean pulmonary artery pressure (mPAP) levels. Moreover, instead of right heart catheterization, this study sought to employ an extreme gradient boosting (XGB) algorithm to predict mPAP levels based on standard echocardiographic parameters.
METHODS AND RESULTS RESULTS
This multicenter study included 737 patients undergoing TTVI for severe TR; among them, 55 patients from one institution served for external validation. Complete echocardiography and right heart catheterization data were available from all patients. The XGB algorithm trained on 10 echocardiographic parameters could reliably predict mPAP levels as evaluated on right heart catheterization data from external validation (Pearson correlation coefficient R: 0.68; p-value: 1.3x10-8). Moreover, predicted mPAP (mPAPpredicted) levels were superior to echocardiographic systolic pulmonary artery pressure (sPAPechocardiography) levels in predicting 2-year mortality after TTVI (area under the curve [AUC]: 0.607 vs. 0.520; p-value: 1.9x10-6). Furthermore, TAPSE/mPAPpredicted was superior to TAPSE/sPAPechocardiography in predicting 2-year mortality after TTVI (AUC: 0.633 vs. 0.586; p-value: 0.008). Finally, patients with preserved RV-PA coupling (defined as TAPSE/mPAPpredicted > 0.617 mm/mmHg) showed significantly higher 2-year survival rates after TTVI than patients with reduced RV-PA coupling (81.5% vs. 58.8%, p-value: < 0.001). Moreover, independent association between TAPSE/mPAPpredicted levels and 2-year mortality after TTVI was confirmed by multivariate regression analysis (p-value: 6.3x10-4).
CONCLUSIONS CONCLUSIONS
Artificial intelligence-enabled RV-PA coupling assessment can refine risk stratification prior to TTVI without necessitating invasive right heart catheterization. A comparison with conservatively treated patients is mandatory to quantify the benefit of TTVI in accordance with RV-PA coupling.

Identifiants

pubmed: 37996066
pii: 7444945
doi: 10.1093/ehjci/jead324
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Vera Fortmeier (V)

Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.

Mark Lachmann (M)

First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich Germany.

Lukas Stolz (L)

DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich Germany.
Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig Maximilians University of Munich, Munich, Germany.

Jennifer von Stein (J)

Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany.

Matthias Unterhuber (M)

Department of Cardiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany.

Mohammad Kassar (M)

Department of Cardiology, Inselspital Bern, Bern University Hospital, Switzerland.

Muhammed Gerçek (M)

Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.

Anne R Schöber (AR)

Department of Cardiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany.

Thomas J Stocker (TJ)

DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich Germany.
Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig Maximilians University of Munich, Munich, Germany.

Hazem Omran (H)

Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.

Maria I Körber (MI)

Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany.

Amelie Hesse (A)

First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich Germany.

Gerhard Harmsen (G)

Department of Physics, University of Johannesburg, Auckland Park, South Africa.

Kai Peter Friedrichs (KP)

Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.

Shinsuke Yuasa (S)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Tanja K Rudolph (TK)

Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.

Michael Joner (M)

DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich Germany.
Department of Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany.

Roman Pfister (R)

Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany.

Stephan Baldus (S)

Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany.

Karl-Ludwig Laugwitz (KL)

First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich Germany.

Stephan Windecker (S)

Department of Cardiology, Inselspital Bern, Bern University Hospital, Switzerland.

Fabien Praz (F)

Department of Cardiology, Inselspital Bern, Bern University Hospital, Switzerland.

Philipp Lurz (P)

Department of Cardiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany.

Jörg Hausleiter (J)

DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich Germany.
Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig Maximilians University of Munich, Munich, Germany.

Volker Rudolph (V)

Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.

Classifications MeSH